$CNO
CNO Financial Group, Inc. Stock $cno

$cno Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000122460823000026 Filed on May 10, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$1.045B	$1.021B
YoY Change	22.18%	21.08%
Cost Of Revenue	$565.9M	$609.7M
YoY Change	66.34%	75.86%
Gross Profit	$478.7M	$410.9M
YoY Change	-7.01%	-17.19%
Gross Profit Margin	45.83%	40.26%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$65.70M
YoY Change		-41.7%
% of Gross Profit		15.99%
Operating Expenses	$886.7M	$937.5M
YoY Change	36.04%	39.97%
Operating Profit	$81.20M	$76.40M
YoY Change	-37.39%	12.35%
Interest Expense	-$40.00M	-$69.50M
YoY Change	-243.88%	-392.02%
% of Operating Profit	-49.26%	-90.97%
Other Income/Expense, Net
YoY Change
Pretax Income	$96.10M	-$1.000M
YoY Change	-45.21%	-100.67%
Income Tax	$22.40M	-$200.0K
% Of Pretax Income	23.31%
Net Earnings	$73.70M	-$800.0K
YoY Change	-45.85%	-100.71%
Net Earnings / Revenue	7.06%	-0.08%
Basic Earnings Per Share	$0.64	-$0.01
Diluted Earnings Per Share	$0.64	-$0.01
COMMON SHARES
Basic Shares Outstanding	114.6M shares	114.2M shares
Diluted Shares Outstanding	115.7M shares	114.5M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$561.9M	$522.1M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$25.35B	$25.34B
YoY Change	0.49%	-7.63%
Other Assets	$1.007B	$988.1M
YoY Change	8.31%	84.97%
Total Long-Term Assets
YoY Change
TOTAL ASSETS
Total Short-Term Assets
Total Long-Term Assets
Total Assets	$34.05B	$34.02B
YoY Change	0.65%	-4.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt	$3.980B	$4.044B
YoY Change	1.95%	3.4%
Other Long-Term Liabilities	$898.9M	$698.9M
YoY Change	26.04%	-23.39%
Total Long-Term Liabilities	$4.879B	$4.743B
YoY Change	5.67%	-1.67%
TOTAL LIABILITIES
Total Short-Term Liabilities
Total Long-Term Liabilities	$4.879B	$4.743B
Total Liabilities	$32.06B	$31.98B
YoY Change	1.37%	0.65%
SHAREHOLDERS EQUITY
Retained Earnings	$1.730B	$1.674B
YoY Change	28.82%	36.82%
Common Stock	$1.999B	$2.022B
YoY Change	-1.71%	-3.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.996B	$2.032B
YoY Change
Total Liabilities & Shareholders Equity	$34.05B	$34.02B
YoY Change	0.65%	-4.1%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	$73.70M	-$800.0K
YoY Change	-45.85%	-100.71%
Depreciation, Depletion And Amortization		$65.70M
YoY Change		-41.7%
Cash From Operating Activities	$141.5M	$81.90M
YoY Change	27.94%	45.21%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$145.2M	$13.90M
YoY Change	-34.0%	4.51%
Cash From Investing Activities	-$145.2M	-$406.7M
YoY Change	-34.0%	-59.74%
FINANCING ACTIVITIES
Cash Dividend Paid		$17.10M
YoY Change		6.21%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	43.50M	$202.0M
YoY Change	-67.73%	-75.25%
NET CHANGE
Cash From Operating Activities	141.5M	$81.90M
Cash From Investing Activities	-145.2M	-$406.7M
Cash From Financing Activities	43.50M	$202.0M
Net Change In Cash	39.80M	-$122.8M
YoY Change	56.69%	-10.82%
FREE CASH FLOW
Cash From Operating Activities	$141.5M	$81.90M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001224608
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-31792
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	CNO Financial Group, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	75-3108137
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	11825 N. Pennsylvania Street
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Carmel,
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	IN
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	46032
CY2023Q1	dei	City Area Code CityAreaCode	(317)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	817-6100
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	114553509	shares
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	59100000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	56000000.0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	23517900000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	23384200000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	21107100000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	20353400000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	106100000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	135300000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	8400000	usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	8000000.0	usd
CY2023Q1	us-gaap	Notes Receivable Net NotesReceivableNet	1676100000	usd
CY2022Q4	us-gaap	Notes Receivable Net NotesReceivableNet	1411900000	usd
CY2023Q1	us-gaap	Policy Loans Receivable PolicyLoansReceivable	123000000.0	usd
CY2022Q4	us-gaap	Policy Loans Receivable PolicyLoansReceivable	121600000	usd
CY2023Q1	us-gaap	Trading Securities Debt TradingSecuritiesDebt	208100000	usd
CY2022Q4	us-gaap	Trading Securities Debt TradingSecuritiesDebt	207900000	usd
CY2023Q1	cno	Investments Held By Variable Interest Entities Allowance For Credit Loss InvestmentsHeldByVariableInterestEntitiesAllowanceForCreditLoss	3500000	usd
CY2022Q4	cno	Investments Held By Variable Interest Entities Allowance For Credit Loss InvestmentsHeldByVariableInterestEntitiesAllowanceForCreditLoss	5500000	usd
CY2023Q1	cno	Investments Held By Variable Interest Entities Amortized Cost InvestmentsHeldByVariableInterestEntitiesAmortizedCost	1060300000	usd
CY2022Q4	cno	Investments Held By Variable Interest Entities Amortized Cost InvestmentsHeldByVariableInterestEntitiesAmortizedCost	1134200000	usd
CY2023Q1	cno	Investments Held By Variable Interest Entities InvestmentsHeldByVariableInterestEntities	1017900000	usd
CY2022Q4	cno	Investments Held By Variable Interest Entities InvestmentsHeldByVariableInterestEntities	1077600000	usd
CY2023Q1	us-gaap	Other Investments OtherInvestments	1097100000	usd
CY2022Q4	us-gaap	Other Investments OtherInvestments	1034700000	usd
CY2023Q1	us-gaap	Investments Investments	25335400000	usd
CY2022Q4	us-gaap	Investments Investments	24342400000	usd
CY2023Q1	cno	Cash And Cash Equivalents At Carrying Value Excluding Variable Interest Entities CashAndCashEquivalentsAtCarryingValueExcludingVariableInterestEntities	425000000.0	usd
CY2022Q4	cno	Cash And Cash Equivalents At Carrying Value Excluding Variable Interest Entities CashAndCashEquivalentsAtCarryingValueExcludingVariableInterestEntities	575700000	usd
CY2023Q1	cno	Cash And Cash Equivalents Held By Variable Interest Entities CashAndCashEquivalentsHeldByVariableInterestEntities	97100000	usd
CY2022Q4	cno	Cash And Cash Equivalents Held By Variable Interest Entities CashAndCashEquivalentsHeldByVariableInterestEntities	69200000	usd
CY2023Q1	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	241300000	usd
CY2022Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	235600000	usd
CY2023Q1	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	197600000	usd
CY2022Q4	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	203700000	usd
CY2023Q1	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1811300000	usd
CY2022Q4	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1770900000	usd
CY2023Q1	us-gaap	Reinsurance Recoverables Allowance ReinsuranceRecoverablesAllowance	2000000.0	usd
CY2022Q4	us-gaap	Reinsurance Recoverables Allowance ReinsuranceRecoverablesAllowance	2000000.0	usd
CY2023Q1	us-gaap	Reinsurance Recoverables On Paid Losses ReinsuranceRecoverablesOnPaidLosses	4189600000	usd
CY2022Q4	us-gaap	Reinsurance Recoverables On Paid Losses ReinsuranceRecoverablesOnPaidLosses	4223400000	usd
CY2023Q1	us-gaap	Market Risk Benefit Asset Amount MarketRiskBenefitAssetAmount	57800000	usd
CY2022Q4	us-gaap	Market Risk Benefit Asset Amount MarketRiskBenefitAssetAmount	65300000	usd
CY2023Q1	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	988100000	usd
CY2022Q4	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	1063400000	usd
CY2023Q1	us-gaap	Separate Account Assets SeparateAccountAssets	2800000	usd
CY2022Q4	us-gaap	Separate Account Assets SeparateAccountAssets	2700000	usd
CY2023Q1	us-gaap	Other Assets OtherAssets	669000000.0	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	580800000	usd
CY2023Q1	us-gaap	Assets Assets	34015000000	usd
CY2022Q4	us-gaap	Assets Assets	33133100000	usd
CY2023Q1	us-gaap	Policyholder Funds PolicyholderFunds	15302900000	usd
CY2022Q4	us-gaap	Policyholder Funds PolicyholderFunds	15234200000	usd
CY2023Q1	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	11623300000	usd
CY2022Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	11240200000	usd
CY2023Q1	us-gaap	Market Risk Benefit Liability Amount MarketRiskBenefitLiabilityAmount	17600000	usd
CY2022Q4	us-gaap	Market Risk Benefit Liability Amount MarketRiskBenefitLiabilityAmount	11300000	usd
CY2023Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	67600000	usd
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	64100000	usd
CY2023Q1	us-gaap	Unearned Premiums UnearnedPremiums	243500000	usd
CY2022Q4	us-gaap	Unearned Premiums UnearnedPremiums	235000000.0	usd
CY2023Q1	us-gaap	Separate Accounts Liability SeparateAccountsLiability	2800000	usd
CY2022Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	2700000	usd
CY2023Q1	us-gaap	Other Liabilities OtherLiabilities	681300000	usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	693900000	usd
CY2023Q1	cno	Investment Borrowings InvestmentBorrowings	1839600000	usd
CY2022Q4	cno	Investment Borrowings InvestmentBorrowings	1639500000	usd
CY2023Q1	cno	Borrowings Related To Variable Interest Entities BorrowingsRelatedToVariableInterestEntities	1065400000	usd
CY2022Q4	cno	Borrowings Related To Variable Interest Entities BorrowingsRelatedToVariableInterestEntities	1104600000	usd
CY2023Q1	us-gaap	Notes Payable NotesPayable	1139200000	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	1138800000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	31983200000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	31364300000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	8000000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	8000000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	114905172	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	114905172	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	114343070	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	114343070	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	1100000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1100000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2021100000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2033800000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1664400000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1957300000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1674000000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1691200000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	2031800000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1768800000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34015000000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33133100000	usd
CY2023Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	625500000	usd
CY2022Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	625000000.0	usd
CY2023Q1	cno	Net Investment Income On General Account Invested Assets NetInvestmentIncomeOnGeneralAccountInvestedAssets	292200000	usd
CY2022Q1	cno	Net Investment Income On General Account Invested Assets NetInvestmentIncomeOnGeneralAccountInvestedAssets	277500000	usd
CY2023Q1	cno	Net Investment Income On Policyholder And Reinsurer Accounts And Other Special Purpose Portfolios NetInvestmentIncomeOnPolicyholderAndReinsurerAccountsAndOtherSpecialPurposePortfolios	50800000	usd
CY2022Q1	cno	Net Investment Income On Policyholder And Reinsurer Accounts And Other Special Purpose Portfolios NetInvestmentIncomeOnPolicyholderAndReinsurerAccountsAndOtherSpecialPurposePortfolios	-69300000	usd
CY2023Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-14600000	usd
CY2022Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	18800000	usd
CY2023Q1	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	0	usd
CY2022Q1	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	-51500000	usd
CY2023Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-14600000	usd
CY2022Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-32700000	usd
CY2023Q1	cno	Fee Revenue And Other Income FeeRevenueAndOtherIncome	52100000	usd
CY2022Q1	cno	Fee Revenue And Other Income FeeRevenueAndOtherIncome	42400000	usd
CY2023Q1	us-gaap	Revenues Revenues	1006000000	usd
CY2022Q1	us-gaap	Revenues Revenues	842900000	usd
CY2023Q1	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	609700000	usd
CY2022Q1	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	333900000	usd
CY2023Q1	us-gaap	Liability For Future Policy Benefit Remeasurement Gain Loss LiabilityForFuturePolicyBenefitRemeasurementGainLoss	-600000	usd
CY2022Q1	us-gaap	Liability For Future Policy Benefit Remeasurement Gain Loss LiabilityForFuturePolicyBenefitRemeasurementGainLoss	-7000000.0	usd
CY2023Q1	us-gaap	Market Risk Benefit Change In Fair Value Gain Loss MarketRiskBenefitChangeInFairValueGainLoss	-14800000	usd
CY2022Q1	us-gaap	Market Risk Benefit Change In Fair Value Gain Loss MarketRiskBenefitChangeInFairValueGainLoss	32700000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	54700000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	23800000	usd
CY2023Q1	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	55500000	usd
CY2022Q1	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	52300000	usd
CY2023Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	271700000	usd
CY2022Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	218300000	usd
CY2023Q1	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	1007000000	usd
CY2022Q1	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	602600000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1000000.0	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	240300000	usd
CY2023Q1	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	-200000	usd
CY2022Q1	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	56900000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-800000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	183400000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	114545000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	118622000	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.55
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	114545000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	121002000	shares
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.52
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-800000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	183400000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	626100000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-2435100000	usd
CY2023Q1	cno	Other Comprehensive Income Loss Adjustment To Discount Rate For Liability For Future Policy Benefits OtherComprehensiveIncomeLossAdjustmentToDiscountRateForLiabilityForFuturePolicyBenefits	263300000	usd
CY2022Q1	cno	Other Comprehensive Income Loss Adjustment To Discount Rate For Liability For Future Policy Benefits OtherComprehensiveIncomeLossAdjustmentToDiscountRateForLiabilityForFuturePolicyBenefits	-1220400000	usd
CY2023Q1	cno	Other Comprehensive Income Loss Adustment To Specific Credit Risk For Market Risk Benefit OtherComprehensiveIncomeLossAdustmentToSpecificCreditRiskForMarketRiskBenefit	-900000	usd
CY2022Q1	cno	Other Comprehensive Income Loss Adustment To Specific Credit Risk For Market Risk Benefit OtherComprehensiveIncomeLossAdustmentToSpecificCreditRiskForMarketRiskBenefit	-6600000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	-10900000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	-7800000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	374600000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-1200300000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	81700000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	-265100000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	292900000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-935200000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	292100000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-751800000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3684700000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	183400000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	265100000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-935200000	usd
CY2022Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	100000000.0	usd
CY2022Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	16000000.0	usd
CY2022Q1	cno	Stock Based Compensation StockBasedCompensation	1500000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	2818400000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1768800000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-800000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-81700000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	292900000	usd
CY2023Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	15100000	usd
CY2023Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	16400000	usd
CY2023Q1	cno	Stock Based Compensation StockBasedCompensation	2400000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	2031800000	usd
CY2023Q1	us-gaap	Proceeds From Insurance Premiums Collected ProceedsFromInsurancePremiumsCollected	582200000	usd
CY2022Q1	us-gaap	Proceeds From Insurance Premiums Collected ProceedsFromInsurancePremiumsCollected	580800000	usd
CY2023Q1	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	315000000.0	usd
CY2022Q1	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	260500000	usd
CY2023Q1	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	50400000	usd
CY2022Q1	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	49800000	usd
CY2023Q1	cno	Insurance Policy Benefits InsurancePolicyBenefits	410900000	usd
CY2022Q1	cno	Insurance Policy Benefits InsurancePolicyBenefits	416800000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	38600000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	9700000	usd
CY2023Q1	cno	Policy Acquisition Costs PolicyAcquisitionCosts	89800000	usd
CY2022Q1	cno	Policy Acquisition Costs PolicyAcquisitionCosts	83700000	usd
CY2023Q1	us-gaap	Payments For Other Operating Activities PaymentsForOtherOperatingActivities	320200000	usd
CY2022Q1	us-gaap	Payments For Other Operating Activities PaymentsForOtherOperatingActivities	309900000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	6200000	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	14600000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	81900000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	56400000	usd
CY2023Q1	cno	Sales Of Investments SalesOfInvestments	486500000	usd
CY2022Q1	cno	Sales Of Investments SalesOfInvestments	1520600000	usd
CY2023Q1	cno	Maturities And Redemptions Of Investments MaturitiesAndRedemptionsOfInvestments	276800000	usd
CY2022Q1	cno	Maturities And Redemptions Of Investments MaturitiesAndRedemptionsOfInvestments	494900000	usd
CY2023Q1	cno	Purchases Of Investments PurchasesOfInvestments	1147700000	usd
CY2022Q1	cno	Purchases Of Investments PurchasesOfInvestments	2995200000	usd
CY2023Q1	us-gaap	Proceeds From Payments For Trading Securities ProceedsFromPaymentsForTradingSecurities	-8400000	usd
CY2022Q1	us-gaap	Proceeds From Payments For Trading Securities ProceedsFromPaymentsForTradingSecurities	-17300000	usd
CY2023Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	13900000	usd
CY2022Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	13300000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-406700000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1010300000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8100000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4000000.0	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	25800000	usd
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	109800000	usd
CY2023Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	17100000	usd
CY2022Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	16100000	usd
CY2023Q1	us-gaap	Proceeds From Annuities And Investment Certificates ProceedsFromAnnuitiesAndInvestmentCertificates	498300000	usd
CY2022Q1	us-gaap	Proceeds From Annuities And Investment Certificates ProceedsFromAnnuitiesAndInvestmentCertificates	1392600000	usd
CY2023Q1	us-gaap	Repayments Of Annuities And Investment Certificates RepaymentsOfAnnuitiesAndInvestmentCertificates	422100000	usd
CY2022Q1	us-gaap	Repayments Of Annuities And Investment Certificates RepaymentsOfAnnuitiesAndInvestmentCertificates	364200000	usd
CY2023Q1	us-gaap	Proceeds From Federal Home Loan Bank Borrowings ProceedsFromFederalHomeLoanBankBorrowings	620500000	usd
CY2022Q1	us-gaap	Proceeds From Federal Home Loan Bank Borrowings ProceedsFromFederalHomeLoanBankBorrowings	0	usd
CY2023Q1	us-gaap	Repayments Of Federal Home Loan Bank Borrowings RepaymentsOfFederalHomeLoanBankBorrowings	420400000	usd
CY2022Q1	us-gaap	Repayments Of Federal Home Loan Bank Borrowings RepaymentsOfFederalHomeLoanBankBorrowings	75300000	usd
CY2023Q1	cno	Repayments Of Investment Borrowings Related To Variable Interest Entities RepaymentsOfInvestmentBorrowingsRelatedToVariableInterestEntities	39500000	usd
CY2022Q1	cno	Repayments Of Investment Borrowings Related To Variable Interest Entities RepaymentsOfInvestmentBorrowingsRelatedToVariableInterestEntities	15000000.0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	202000000.0	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	816200000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-122800000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-137700000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	644900000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	731700000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	522100000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	594000000.0	usd
CY2020Q4	us-gaap	Market Risk Benefit Asset Amount MarketRiskBenefitAssetAmount	0	usd
CY2020Q4	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	199400000	usd
CY2023Q1	cno	Deferred Profit Liability DeferredProfitLiability	57700000	usd
CY2020Q4	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	249400000	usd
CY2020Q4	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1027800000	usd
CY2020Q4	us-gaap	Reinsurance Recoverables On Paid Losses ReinsuranceRecoverablesOnPaidLosses	4584300000	usd
CY2020Q4	us-gaap	Assets Assets	35339900000	usd
CY2020Q4	us-gaap	Policyholder Funds PolicyholderFunds	12540600000	usd
CY2020Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	11744200000	usd
CY2020Q4	us-gaap	Market Risk Benefit Liability Amount MarketRiskBenefitLiabilityAmount	0	usd
CY2020Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	561800000	usd
CY2020Q4	us-gaap	Liabilities Liabilities	29855700000	usd
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	752300000	usd
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2186100000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	5484200000	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1293000000	usd
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-561500000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	2818400000	usd
CY2021Q1	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	259600000	usd
CY2021Q1	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1485800000	usd
CY2021Q1	us-gaap	Reinsurance Recoverables Gross ReinsuranceRecoverablesGross	4728400000	usd
CY2021Q1	us-gaap	Market Risk Benefit Asset Amount MarketRiskBenefitAssetAmount	2500000	usd
CY2021Q1	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	806400000	usd
CY2021Q1	us-gaap	Policyholder Funds PolicyholderFunds	12367700000	usd
CY2021Q1	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	15704900000	usd
CY2021Q1	us-gaap	Market Risk Benefit Liability Amount MarketRiskBenefitLiabilityAmount	114800000	usd
CY2021Q1	us-gaap	Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense	91700000	usd
CY2023Q1	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments Having No Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsHavingNoAllowanceForCreditLosses	-937100000	usd
CY2022Q4	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments Having No Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsHavingNoAllowanceForCreditLosses	-1247000000	usd
CY2023Q1	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments With Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsWithAllowanceForCreditLosses	-1453600000	usd
CY2022Q4	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments With Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsWithAllowanceForCreditLosses	-1780700000	usd
CY2023Q1	cno	Accumulated Other Comprehensive Income Loss Changes In Discount Rate For Liability For Future Policy Benefit AccumulatedOtherComprehensiveIncomeLossChangesInDiscountRateForLiabilityForFuturePolicyBenefit	237400000	usd
CY2022Q4	cno	Accumulated Other Comprehensive Income Loss Changes In Discount Rate For Liability For Future Policy Benefit AccumulatedOtherComprehensiveIncomeLossChangesInDiscountRateForLiabilityForFuturePolicyBenefit	500700000	usd
CY2023Q1	cno	Accumulated Other Comprehensive Income Loss Changed In Instrument Specific Credit Risk For Market Risk Benefits AccumulatedOtherComprehensiveIncomeLossChangedInInstrumentSpecificCreditRiskForMarketRiskBenefits	13100000	usd
CY2022Q4	cno	Accumulated Other Comprehensive Income Loss Changed In Instrument Specific Credit Risk For Market Risk Benefits AccumulatedOtherComprehensiveIncomeLossChangedInInstrumentSpecificCreditRiskForMarketRiskBenefits	12200000	usd
CY2023Q1	cno	Accumulated Other Comprehensive Income Loss Deferred Income Tax Liabilities AccumulatedOtherComprehensiveIncomeLossDeferredIncomeTaxLiabilities	475800000	usd
CY2022Q4	cno	Accumulated Other Comprehensive Income Loss Deferred Income Tax Liabilities AccumulatedOtherComprehensiveIncomeLossDeferredIncomeTaxLiabilities	557500000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1664400000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1957300000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	140100000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	138700000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	2209300000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	2080000000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	1871800000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	1742800000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	12328700000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	10726200000	usd
CY2023Q1	cno	Available For Sale Securities Debt Maturities Amortized Cost Excluding Structured Securities AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostExcludingStructuredSecurities	16549900000	usd
CY2023Q1	cno	Available For Sale Securities Debt Maturities Fair Value Excluding Structured Securities AvailableForSaleSecuritiesDebtMaturitiesFairValueExcludingStructuredSecurities	14687700000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost	6968000000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	6419400000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	23517900000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	21107100000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	112000000.0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	110800000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	1913700000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	1790200000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	2098900000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	1910400000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	12629400000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	10523200000	usd
CY2022Q4	cno	Available For Sale Securities Debt Maturities Amortized Cost Excluding Structured Securities AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostExcludingStructuredSecurities	16754000000	usd
CY2022Q4	cno	Available For Sale Securities Debt Maturities Fair Value Excluding Structured Securities AvailableForSaleSecuritiesDebtMaturitiesFairValueExcludingStructuredSecurities	14334600000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost	6630200000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	6018800000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	23384200000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	20353400000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	3088700000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	108600000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	6207400000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	950900000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	9296100000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1059500000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	7636900000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	835200000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	1897500000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	471600000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	9534400000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1306800000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	56000000.0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	3000000.0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Purchased With Credit Deterioration Increase DebtSecuritiesAvailableForSaleAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not To Sell Before Recovery Credit Loss Previously Recorded Expense Reversal DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal	800000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Securities Sold DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold	700000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Sell Before Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossSellBeforeRecovery	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Writeoff DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossRecovery	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	59100000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	7600000	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	14400000	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Purchased With Credit Deterioration Increase DebtSecuritiesAvailableForSaleAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not To Sell Before Recovery Credit Loss Previously Recorded Expense Reversal DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal	15000000.0	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Securities Sold DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold	400000	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Sell Before Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossSellBeforeRecovery	0	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Writeoff DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff	0	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossRecovery	0	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	36600000	usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	8000000.0	usd
CY2021Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	5600000	usd
CY2023Q1	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	-400000	usd
CY2022Q1	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	500000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Loss Purchased With Credit Deterioration Increase FinancingReceivableAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	usd
CY2022Q1	us-gaap	Financing Receivable Allowance For Credit Loss Purchased With Credit Deterioration Increase FinancingReceivableAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	0	usd
CY2022Q1	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	0	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Losses Recovery FinancingReceivableAllowanceForCreditLossesRecovery	0	usd
CY2022Q1	us-gaap	Financing Receivable Allowance For Credit Losses Recovery FinancingReceivableAllowanceForCreditLossesRecovery	0	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	8400000	usd
CY2022Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	5100000	usd
CY2023Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-14600000	usd
CY2022Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	18800000	usd
CY2023Q1	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	1500000	usd
CY2022Q1	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	30700000	usd
CY2023Q1	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	400000	usd
CY2022Q1	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-1200000	usd
CY2023Q1	cno	Increase Decrease In Fair Value Of Other Securities IncreaseDecreaseInFairValueOfOtherSecurities	1100000	usd
CY2022Q1	cno	Increase Decrease In Fair Value Of Other Securities IncreaseDecreaseInFairValueOfOtherSecurities	-19600000	usd
CY2023Q1	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	0	usd
CY2022Q1	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	-51500000	usd
CY2023Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-14600000	usd
CY2022Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-32700000	usd
CY2023Q1	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	-2000000	usd
CY2022Q1	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	2200000	usd
CY2023Q1	cno	Increase Decrease In Equity Securities Fvni Held At End Of Period IncreaseDecreaseInEquitySecuritiesFVNIHeldAtEndOfPeriod	300000	usd
CY2022Q1	cno	Increase Decrease In Equity Securities Fvni Held At End Of Period IncreaseDecreaseInEquitySecuritiesFVNIHeldAtEndOfPeriod	-5200000	usd
CY2023Q1	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	-2500000	usd
CY2022Q1	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	-12800000	usd
CY2023Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-14600000	usd
CY2023Q1	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	1500000	usd
CY2022Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-32700000	usd
CY2022Q1	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	30700000	usd
CY2023Q1	cno	Numberof Investmentsin Defaultor Considered Nonperforming NumberofInvestmentsinDefaultorConsideredNonperforming	0	investment
CY2023Q1	cno	Available For Sale Securities Value Of Securities Sold AvailableForSaleSecuritiesValueOfSecuritiesSold	288500000	usd
CY2022Q1	cno	Available For Sale Securities Value Of Securities Sold AvailableForSaleSecuritiesValueOfSecuritiesSold	786600000	usd
CY2023Q1	cno	Liability For Future Policy Benefit Before Reinsurance Reserve LiabilityForFuturePolicyBenefitBeforeReinsuranceReserve	2593300000	usd
CY2022Q1	cno	Liability For Future Policy Benefit Before Reinsurance Reserve LiabilityForFuturePolicyBenefitBeforeReinsuranceReserve	2626500000	usd
CY2023Q1	cno	Liability For Future Policy Benefit Deferred Profit Liability LiabilityForFuturePolicyBenefitDeferredProfitLiability	57700000	usd
CY2022Q1	cno	Liability For Future Policy Benefit Deferred Profit Liability LiabilityForFuturePolicyBenefitDeferredProfitLiability	51300000	usd
CY2023Q1	cno	Liability For Future Policy Benefit Fas Reserves Excluding Policyholder LiabilityForFuturePolicyBenefitFASReservesExcludingPolicyholder	410500000	usd
CY2022Q1	cno	Liability For Future Policy Benefit Fas Reserves Excluding Policyholder LiabilityForFuturePolicyBenefitFASReservesExcludingPolicyholder	273100000	usd
CY2023Q1	cno	Liability For Future Policy Benefits Payment For Benefits Reserve LiabilityForFuturePolicyBenefitsPaymentForBenefitsReserve	34700000	usd
CY2022Q1	cno	Liability For Future Policy Benefits Payment For Benefits Reserve LiabilityForFuturePolicyBenefitsPaymentForBenefitsReserve	34600000	usd
CY2023Q1	cno	Policyholder Account Balance Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense PolicyholderAccountBalanceLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense	11623300000	usd
CY2022Q1	cno	Policyholder Account Balance Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense PolicyholderAccountBalanceLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense	13206100000	usd
CY2022Q4	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-54000000.0	usd
CY2021Q4	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	86200000	usd
CY2022Q4	cno	Market Risk Benefit Effect Of Changes In Instrument Specific Credit Risk MarketRiskBenefitEffectOfChangesInInstrumentSpecificCreditRisk	12200000	usd
CY2021Q4	cno	Market Risk Benefit Effect Of Changes In Instrument Specific Credit Risk MarketRiskBenefitEffectOfChangesInInstrumentSpecificCreditRisk	12100000	usd
CY2022Q4	us-gaap	Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-41800000	usd
CY2021Q4	us-gaap	Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	98300000	usd
CY2023Q1	cno	Market Risk Benefit Issuance Net MarketRiskBenefitIssuanceNet	100000	usd
CY2022Q1	cno	Market Risk Benefit Issuance Net MarketRiskBenefitIssuanceNet	-800000	usd
CY2023Q1	us-gaap	Market Risk Benefit Interest Expense MarketRiskBenefitInterestExpense	5200000	usd
CY2022Q1	us-gaap	Market Risk Benefit Interest Expense MarketRiskBenefitInterestExpense	3400000	usd
CY2023Q1	us-gaap	Market Risk Benefit Attributed Fee Collected MarketRiskBenefitAttributedFeeCollected	0	usd
CY2022Q1	us-gaap	Market Risk Benefit Attributed Fee Collected MarketRiskBenefitAttributedFeeCollected	0	usd
CY2023Q1	us-gaap	Market Risk Benefit Benefit Payment MarketRiskBenefitBenefitPayment	0	usd
CY2022Q1	us-gaap	Market Risk Benefit Benefit Payment MarketRiskBenefitBenefitPayment	0	usd
CY2023Q1	us-gaap	Market Risk Benefit Increase Decrease From Interest Rate Change MarketRiskBenefitIncreaseDecreaseFromInterestRateChange	12300000	usd
CY2022Q1	us-gaap	Market Risk Benefit Increase Decrease From Interest Rate Change MarketRiskBenefitIncreaseDecreaseFromInterestRateChange	-35300000	usd
CY2023Q1	us-gaap	Market Risk Benefit Increase Decrease From Equity Market Change MarketRiskBenefitIncreaseDecreaseFromEquityMarketChange	5300000	usd
CY2022Q1	us-gaap	Market Risk Benefit Increase Decrease From Equity Market Change MarketRiskBenefitIncreaseDecreaseFromEquityMarketChange	-6800000	usd
CY2023Q1	us-gaap	Market Risk Benefit Increase Decrease From Volatility MarketRiskBenefitIncreaseDecreaseFromVolatility	-7400000	usd
CY2022Q1	us-gaap	Market Risk Benefit Increase Decrease From Volatility MarketRiskBenefitIncreaseDecreaseFromVolatility	4400000	usd
CY2023Q1	us-gaap	Market Risk Benefit Increase Decrease From Actual Policyholder Behavior Different From Expected MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected	600000	usd
CY2022Q1	us-gaap	Market Risk Benefit Increase Decrease From Actual Policyholder Behavior Different From Expected MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected	300000	usd
CY2023Q1	cno	Market Risk Benefit Increase Decrease From Future Expected Policyholder Behavior Assumption Other MarketRiskBenefitIncreaseDecreaseFromFutureExpectedPolicyholderBehaviorAssumptionOther	0	usd
CY2022Q1	cno	Market Risk Benefit Increase Decrease From Future Expected Policyholder Behavior Assumption Other MarketRiskBenefitIncreaseDecreaseFromFutureExpectedPolicyholderBehaviorAssumptionOther	0	usd
CY2023Q1	cno	Market Risk Benefit Increase Decrease From Future Expected Policyholder Behavior Assumption Risk Margin MarketRiskBenefitIncreaseDecreaseFromFutureExpectedPolicyholderBehaviorAssumptionRiskMargin	0	usd
CY2022Q1	cno	Market Risk Benefit Increase Decrease From Future Expected Policyholder Behavior Assumption Risk Margin MarketRiskBenefitIncreaseDecreaseFromFutureExpectedPolicyholderBehaviorAssumptionRiskMargin	0	usd
CY2023Q1	us-gaap	Market Risk Benefit Increase Decrease From Other Assumption MarketRiskBenefitIncreaseDecreaseFromOtherAssumption	-1400000	usd
CY2022Q1	us-gaap	Market Risk Benefit Increase Decrease From Other Assumption MarketRiskBenefitIncreaseDecreaseFromOtherAssumption	2100000	usd
CY2023Q1	us-gaap	Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-27100000	usd
CY2022Q1	us-gaap	Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	65600000	usd
CY2023Q1	cno	Market Risk Benefit Effect Of Changes In Instrument Specific Credit Risk MarketRiskBenefitEffectOfChangesInInstrumentSpecificCreditRisk	-13100000	usd
CY2022Q1	cno	Market Risk Benefit Effect Of Changes In Instrument Specific Credit Risk MarketRiskBenefitEffectOfChangesInInstrumentSpecificCreditRisk	-18700000	usd
CY2023Q1	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-40200000	usd
CY2022Q1	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	46900000	usd
CY2023Q1	us-gaap	Market Risk Benefit Reinsurance Recoverable After Allowance MarketRiskBenefitReinsuranceRecoverableAfterAllowance	0	usd
CY2022Q1	us-gaap	Market Risk Benefit Reinsurance Recoverable After Allowance MarketRiskBenefitReinsuranceRecoverableAfterAllowance	0	usd
CY2023Q1	us-gaap	Market Risk Benefit After Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitAfterReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-40200000	usd
CY2022Q1	us-gaap	Market Risk Benefit After Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitAfterReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	46900000	usd
CY2023Q1	us-gaap	Market Risk Benefit Asset Amount MarketRiskBenefitAssetAmount	57800000	usd
CY2022Q1	us-gaap	Market Risk Benefit Asset Amount MarketRiskBenefitAssetAmount	16900000	usd
CY2023Q1	us-gaap	Market Risk Benefit Liability Amount MarketRiskBenefitLiabilityAmount	17600000	usd
CY2022Q1	us-gaap	Market Risk Benefit Liability Amount MarketRiskBenefitLiabilityAmount	63800000	usd
CY2023Q1	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-40200000	usd
CY2022Q1	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	46900000	usd
CY2023Q1	us-gaap	Market Risk Benefit Net Amount At Risk MarketRiskBenefitNetAmountAtRisk	58900000	usd
CY2022Q1	us-gaap	Market Risk Benefit Net Amount At Risk MarketRiskBenefitNetAmountAtRisk	107400000	usd
CY2023Q1	us-gaap	Net Amount At Risk By Product And Guarantee Weighted Average Attained Age1 NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1	P68Y
CY2022Q1	us-gaap	Net Amount At Risk By Product And Guarantee Weighted Average Attained Age1 NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1	P68Y
CY2023Q1	us-gaap	Liability For Future Policy Benefit Gross Premium Income LiabilityForFuturePolicyBenefitGrossPremiumIncome	601400000	usd
CY2022Q1	us-gaap	Liability For Future Policy Benefit Gross Premium Income LiabilityForFuturePolicyBenefitGrossPremiumIncome	600300000	usd
CY2023Q1	us-gaap	Liability For Future Policy Benefit Interest Expense LiabilityForFuturePolicyBenefitInterestExpense	119400000	usd
CY2022Q1	us-gaap	Liability For Future Policy Benefit Interest Expense LiabilityForFuturePolicyBenefitInterestExpense	118800000	usd
CY2023Q1	us-gaap	Policyholder Funds PolicyholderFunds	15302900000	usd
CY2022Q1	us-gaap	Policyholder Funds PolicyholderFunds	14725600000	usd
CY2023Q1	us-gaap	Policyholder Funds PolicyholderFunds	15302900000	usd
CY2022Q1	us-gaap	Policyholder Funds PolicyholderFunds	14725600000	usd
CY2022Q4	cno	Deferred Policy Acquisition Cost Net Of Sales Inducements DeferredPolicyAcquisitionCostNetOfSalesInducements	1690400000	usd
CY2023Q1	us-gaap	Deferred Policy Acquisition Costs Additions DeferredPolicyAcquisitionCostsAdditions	84200000	usd
CY2023Q1	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	46600000	usd
CY2023Q1	cno	Deferred Policy Acquisition Cost Net Of Sales Inducements DeferredPolicyAcquisitionCostNetOfSalesInducements	1728000000	usd
CY2021Q4	cno	Deferred Policy Acquisition Cost Net Of Sales Inducements DeferredPolicyAcquisitionCostNetOfSalesInducements	1553300000	usd
CY2022Q1	us-gaap	Deferred Policy Acquisition Costs Additions DeferredPolicyAcquisitionCostsAdditions	79000000.0	usd
CY2022Q1	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	43000000.0	usd
CY2022Q1	cno	Deferred Policy Acquisition Cost Net Of Sales Inducements DeferredPolicyAcquisitionCostNetOfSalesInducements	1589300000	usd
CY2022Q4	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	203700000	usd
CY2023Q1	us-gaap	Present Value Of Future Insurance Profits Amortization Expense1 PresentValueOfFutureInsuranceProfitsAmortizationExpense1	6100000	usd
CY2023Q1	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	197600000	usd
CY2021Q4	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	230100000	usd
CY2022Q1	us-gaap	Present Value Of Future Insurance Profits Amortization Expense1 PresentValueOfFutureInsuranceProfitsAmortizationExpense1	6900000	usd
CY2022Q1	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	223200000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-800000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-800000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	183400000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	183400000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	114545000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	118622000	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2022Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2380000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	114545000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	121002000	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2182000	shares
CY2023Q1	cno	Numberof Product Lines NumberofProductLines	3	product_line
CY2023Q1	cno	Numberof Product Lines NumberofProductLines	3	product_line
CY2023Q1	cno	Segment Revenues SegmentRevenues	1000500000	usd
CY2022Q1	cno	Segment Revenues SegmentRevenues	869100000	usd
CY2023Q1	cno	Impact Of Forfeited Annual Forward Options Purchased Related To Fixed Indexed Annuities ImpactOfForfeitedAnnualForwardOptionsPurchasedRelatedToFixedIndexedAnnuities	0	usd
CY2022Q1	cno	Impact Of Forfeited Annual Forward Options Purchased Related To Fixed Indexed Annuities ImpactOfForfeitedAnnualForwardOptionsPurchasedRelatedToFixedIndexedAnnuities	-1600000	usd
CY2023Q1	cno	Segment Expenses SegmentExpenses	924100000	usd
CY2022Q1	cno	Segment Expenses SegmentExpenses	784600000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	76400000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	84500000	usd
CY2023Q1	cno	Income Tax Benefit On Operating Income Loss IncomeTaxBenefitOnOperatingIncomeLoss	17800000	usd
CY2022Q1	cno	Income Tax Benefit On Operating Income Loss IncomeTaxBenefitOnOperatingIncomeLoss	20000000.0	usd
CY2023Q1	cno	Operating Income Loss Net Of Tax OperatingIncomeLossNetOfTax	58600000	usd
CY2022Q1	cno	Operating Income Loss Net Of Tax OperatingIncomeLossNetOfTax	64500000	usd
CY2023Q1	us-gaap	Revenues Revenues	1006000000	usd
CY2022Q1	us-gaap	Revenues Revenues	842900000	usd
CY2023Q1	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	1007000000	usd
CY2022Q1	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	602600000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1000000.0	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	240300000	usd
CY2023Q1	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	-200000	usd
CY2022Q1	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	56900000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-800000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	183400000	usd
CY2023Q1	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Net EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet	88000000	usd
CY2023Q1	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	20000000.0	usd
CY2022Q1	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-79400000	usd
CY2022Q1	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.027
CY2023Q1	cno	Loss Limitation Based On Loss Of Non Life Entities LossLimitationBasedOnLossOfNonLifeEntities	0.35
CY2023Q1	us-gaap	Ceded Premiums Written CededPremiumsWritten	48300000	usd
CY2022Q1	us-gaap	Ceded Premiums Written CededPremiumsWritten	52000000	usd
CY2023Q1	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	134900000	usd
CY2022Q1	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	93900000	usd
CY2023Q1	us-gaap	Assumed Premiums Written AssumedPremiumsWritten	4100000	usd
CY2022Q1	us-gaap	Assumed Premiums Written AssumedPremiumsWritten	4900000	usd
CY2023Q1	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	4700000	usd
CY2022Q1	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	6100000	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.233
CY2023Q1	cno	Federal Long Term Tax Exempt Rate FederalLongTermTaxExemptRate	0.0292
CY2023Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	14000000.0	usd
CY2022Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4400000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-14200000	usd
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	52500000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-200000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	56900000	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.004
CY2022Q1	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.027
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.237
CY2023Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	149900000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	166000000.0	usd
CY2023Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2500000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2500000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Policyholder Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities	329400000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Policyholder Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities	298500000	usd
CY2023Q1	cno	Deferred Tax Assets Indirect Costs Allocableto Self Constructed Real Estate Assets DeferredTaxAssetsIndirectCostsAllocabletoSelfConstructedRealEstateAssets	224400000	usd
CY2022Q4	cno	Deferred Tax Assets Indirect Costs Allocableto Self Constructed Real Estate Assets DeferredTaxAssetsIndirectCostsAllocabletoSelfConstructedRealEstateAssets	214800000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Other Comprehensive Loss DeferredTaxAssetsOtherComprehensiveLoss	470100000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other Comprehensive Loss DeferredTaxAssetsOtherComprehensiveLoss	552400000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	7300000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1176300000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1241500000	usd
CY2023Q1	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	34800000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	37200000	usd
CY2023Q1	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	152100000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	148900000	usd
CY2023Q1	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1500000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	usd
CY2023Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	188400000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	186100000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	987900000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1055400000	usd
CY2023Q1	cno	Prepaid Accrued Income Taxes Current PrepaidAccruedIncomeTaxesCurrent	200000	usd
CY2022Q4	cno	Prepaid Accrued Income Taxes Current PrepaidAccruedIncomeTaxesCurrent	8000000.0	usd
CY2023Q1	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	988100000	usd
CY2022Q4	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	1063400000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	987900000	usd
CY2023Q1	cno	Loss Limitation Based On Income Of Life Insurance Company LossLimitationBasedOnIncomeOfLifeInsuranceCompany	0.35
CY2023Q1	cno	Ownership Change Threshold Restricting Net Operating Loss Usage OwnershipChangeThresholdRestrictingNetOperatingLossUsage	0.50
CY2023Q1	cno	Nonoperating Loss Carryforwards NonoperatingLossCarryforwards	714000000.0	usd
CY2023Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2500000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2500000	usd
CY2023Q1	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	10800000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	11200000	usd
CY2023Q1	us-gaap	Notes Payable NotesPayable	1139200000	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	1138800000	usd
CY2023Q1	cno	Number Of Insurance Subsidiaries That Are Members Of The Federal Home Loan Bank NumberOfInsuranceSubsidiariesThatAreMembersOfTheFederalHomeLoanBank	3	subsidiary
CY2023Q1	cno	Interest Expense On Fhlb Borrowings InterestExpenseOnFhlbBorrowings	21700000	usd
CY2022Q1	cno	Interest Expense On Fhlb Borrowings InterestExpenseOnFhlbBorrowings	2400000	usd
CY2023Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	15100000	usd
CY2023Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	171800000	usd
CY2023Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	16400000	usd
CY2023Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.14
CY2023Q1	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LITIGATION AND OTHER LEGAL PROCEEDINGS</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are involved in various legal actions in the normal course of business, in which claims for compensatory and punitive damages are asserted, some for substantial amounts. We recognize an estimated loss from these loss contingencies when we believe it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Some of the pending matters have been filed as purported class actions and some actions have been filed in certain jurisdictions that permit punitive damage awards that are disproportionate to the actual damages incurred. The amounts sought in certain of these actions are often large or indeterminate and the ultimate outcome of certain actions is difficult to predict. In the event of an adverse outcome in one or more of these matters, there is a possibility that the ultimate liability may be in excess of the liabilities we have established and could have a material adverse effect on our business, financial condition, results of operations and cash flows. In addition, the resolution of pending or future litigation may involve modifications to the terms of outstanding insurance policies or could impact the timing and amount of rate increases, which could adversely affect the future profitability of the related insurance policies. Based upon information presently available, and in light of legal, factual and other defenses available to the Company and its subsidiaries, the Company does not believe that it is probable that the ultimate liability from either pending or threatened legal actions, after consideration of existing loss provisions, will have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows. However, given the inherent difficulty in predicting the outcome of legal proceedings, there exists the possibility that such legal actions could have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the inherent difficulty of predicting litigation outcomes, particularly those that will be decided by a jury, some matters purport to seek substantial or an unspecified amount of damages for unsubstantiated conduct spanning several years based on complex legal theories and damages models. The alleged damages typically are indeterminate or not factually supported in the complaint, and, in any event, the Company's experience indicates that monetary demands for damages often bear little relation to the ultimate loss. In some cases, plaintiffs are seeking to certify classes in the litigation and class certification either has been denied or is pending and we have filed oppositions to class certification or sought to decertify a prior class certification. In addition, for many of these cases: (i) there is uncertainty as to the outcome of pending appeals or motions; (ii) there are significant factual issues to be resolved; and/or (iii) there are novel legal issues presented. Accordingly, the Company cannot reasonably estimate the possible loss or range of loss in excess of amounts accrued, if any, or predict the timing of the eventual resolution of these matters. The Company reviews these matters on an ongoing basis. When assessing reasonably possible and probable outcomes, the Company bases its assessment on the expected ultimate outcome following all appeals.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 9, 2019, Bankers Conseco Life Insurance Company ("BCLIC") and Washington National commenced an action entitled</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Bankers Conseco Life Insurance Company and Washington National Insurance Company v. Wilmington Trust, National Association</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the Supreme Court of the State of New York, County of New York, Commercial Division (the "Wilmington Action"). BCLIC and Washington National seek an unspecified amount of damages, costs, attorney's fees, and other relief as the court deems appropriate. In the Wilmington Action, BCLIC and Washington National assert claims against Wilmington Trust, National Association ("Wilmington") for breaching its express contractual obligations under four trust agreements pursuant to which Wilmington was the trustee in regard to trust assets ceded as part of reinsurance agreements with Beechwood Re Ltd. ("BRe"), as well as for breaching its fiduciary duties to BCLIC and Washington National. The Court </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">granted Wilmington's motion to dismiss this litigation. BCLIC and Washington National appealed the Court's decision. On April 20, 2021, the New York Appellate Division of the Supreme Court, First Judicial Department unanimously reversed the trial court and reinstated breach of contract and breach of fiduciary duty claims against Wilmington. The Wilmington Action is currently pending in the Supreme Court of the State of New York, County of New York, Commercial Division. </span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 7, 2019, the Joint Official Liquidators of Platinum Partners Value Arbitrage Fund L.P. (in Official Liquidation) and Principal Growth Strategies, LLC, commenced suit against, among others, CNO Financial Group, Inc., BCLIC, Washington National and 40\|86 Advisors, Inc. (collectively, the "CNO Parties") in Delaware Chancery Court. Plaintiffs seek an unspecified amount of damages, costs, attorney's fees, and other relief as the court deems appropriate. Plaintiffs allege that the CNO Parties were unjustly enriched when they terminated BCLIC and Washington National's reinsurance agreements with BRe and recaptured assets from reinsurance trusts, in particular, Agera securities. Plaintiffs contend that the Agera securities were fraudulently transferred to the reinsurance trusts by other Platinum-related entities and they are seeking to claw back those Agera securities, or the value of those assets, from the CNO Parties. The CNO Parties are vigorously contesting the plaintiff's claims. The CNO Parties had removed the case to the United States District Court for the District of Delaware but on April 6, 2020, the District Court granted the plaintiff's motion to remand the case back to the Delaware Chancery Court. Plaintiffs have filed an Amended Complaint and the CNO Parties have moved to dismiss the Amended Complaint. The Delaware Chancery Court denied the CNO Parties’ motions to dismiss the Amended Complaint on the basis of forum non conveniens, but granted the CNO Parties’ motion to stay the case pending the conclusion of a related matter. After the stay is lifted, the court will address the CNO Parties’ and other defendants’ motions to dismiss the Amended Complaint on numerous other grounds.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 28, 2019, BCLIC and Washington National commenced an action entitled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bankers Conseco Life Insurance Company and Washington National Insurance Company v. KPMG LLP,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Supreme Court of the State of New York, County of New York, Commercial Division (the "KPMG Action"). BCLIC and Washington National seek an unspecified amount of damages, costs, attorney's fees, and other relief as the court deems appropriate. In the KPMG Action, BCLIC and Washington National assert claims against KPMG LLP ("KPMG") for aiding and abetting fraud, constructive fraud and negligent misrepresentation arising from KPMG's alleged role in the Platinum Partners' scheme to defraud BCLIC and Washington National into reinsuring its long-term care business with BRe. The Court granted KPMG’s motion to dismiss this litigation. BCLIC and Washington National appealed the Court's decision. On December 1, 2020, the New York Appellate Division of the Supreme Court, First Judicial Department unanimously reversed the trial court and reinstated the aiding and abetting claim against KPMG. The KPMG Action is currently pending in the Supreme Court of the State of New York, County of New York, Commercial Division.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2012, plaintiffs William Jeffrey Burnett and Joe H. Camp commenced an action entitled Burnett v. Conseco Life Ins. Co. against, among others, CNO Financial Group, Inc. and CNO Services, LLC (collectively, the "CNO Entities") in the United States District Court for the Central District of California on behalf of a putative class of former interest-sensitive whole life insurance policyholders who surrendered their policies or let them lapse. Plaintiffs' first amended complaint alleges that the CNO Entities are liable under an alter ego theory for Conseco Life Insurance Company's purported breach of the optional premium payment provision (the "Optional Premium Payment") of plaintiffs' insurance policies. In January 2018, the case was transferred to the United States District Court for the Southern District of Indiana (the "Court"). On August 17, 2020, the Court denied the CNO Entities' motions to dismiss. On January 13, 2021, the Court granted final approval of a class action settlement between plaintiffs and co-defendant Conseco Life Insurance Company (n/k/a Wilco Life Insurance Company). The case remains pending against the CNO Entities. On March 25, 2022, the Court certified a Rule 23(b)(3) class of under 2,000 policyholders who invoked the policy's Optional Premium Payment prior to October 2008 and who surrendered their policies between October 7, 2008 and September 1, 2011. The Court's certification order acknowledged the existence of individualized issues of causation and damages, which the Court stated could be addressed in individualized proceedings following a class trial on the alter ego allegations and the meaning of the subject insurance policy language. The CNO Entities continue to vigorously defend the case.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Examinations and Fines</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance companies face significant risks related to regulatory investigations and actions. Regulatory investigations generally result from matters related to sales or underwriting practices, payment of contingent or other sales commissions, claim payments and procedures, product design, product disclosure, additional premium charges for premiums paid on a periodic basis, denial or delay of benefits, charging excessive or impermissible fees on products, procedures related to canceling policies, changing the way cost of insurance charges are calculated for certain life insurance products or recommending </span></div>unsuitable products to customers. We are, in the ordinary course of our business, subject to various examinations, inquiries and information requests from state, federal and other authorities. The ultimate outcome of these regulatory actions (including the costs of complying with information requests and policy reviews) cannot be predicted with certainty. In the event of an unfavorable outcome in one or more of these matters, the ultimate liability may be in excess of liabilities we have established and we could suffer significant reputational harm as a result of these matters, which could also have a material adverse effect on our business, financial condition, results of operations or cash flows.
CY2019Q2	cno	Number Of Trust Agreements NumberOfTrustAgreements	4	trust_agreement
CY2022Q1	cno	Number Of Policyholders NumberOfPolicyholders	2000	policyholder
CY2023Q1	cno	Gain Losson Investments Excluding Cash Expenses GainLossonInvestmentsExcludingCashExpenses	-14600000	usd
CY2022Q1	cno	Gain Losson Investments Excluding Cash Expenses GainLossonInvestmentsExcludingCashExpenses	-32700000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-800000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	183400000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	65700000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	61100000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-6400000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	42300000	usd
CY2023Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	173300000	usd
CY2022Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	-152400000	usd
CY2023Q1	cno	Change In Accrued Investment Income Amortization Of Premium Or Discount On Investments And Fair Value Of Investments ChangeInAccruedInvestmentIncomeAmortizationOfPremiumOrDiscountOnInvestmentsAndFairValueOfInvestments	-27900000	usd
CY2022Q1	cno	Change In Accrued Investment Income Amortization Of Premium Or Discount On Investments And Fair Value Of Investments ChangeInAccruedInvestmentIncomeAmortizationOfPremiumOrDiscountOnInvestmentsAndFairValueOfInvestments	52200000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Policy Acquisition Costs IncreaseDecreaseInDeferredPolicyAcquisitionCosts	89800000	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Policy Acquisition Costs IncreaseDecreaseInDeferredPolicyAcquisitionCosts	83700000	usd
CY2023Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-46800000	usd
CY2022Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-79200000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	81900000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	56400000	usd
CY2023Q1	cno	Share Based Compensation Noncash Portion ShareBasedCompensationNoncashPortion	6500000	usd
CY2022Q1	cno	Share Based Compensation Noncash Portion ShareBasedCompensationNoncashPortion	7200000	usd
CY2023Q1	cno	Variable Interest Entity Amortized Cost Securities Held VariableInterestEntityAmortizedCostSecuritiesHeld	1060300000	usd
CY2023Q1	cno	Variable Interest Entity Gross Unrealized Gains Fixed Maturity Securities VariableInterestEntityGrossUnrealizedGainsFixedMaturitySecurities	1400000	usd
CY2023Q1	cno	Variable Interest Entity Gross Unrealized Losses Fixed Maturity Securities VariableInterestEntityGrossUnrealizedLossesFixedMaturitySecurities	40300000	usd
CY2023Q1	cno	Variable Interest Entity Fixed Maturity Securities Allowance For Credit Loss VariableInterestEntityFixedMaturitySecuritiesAllowanceForCreditLoss	3500000	usd
CY2023Q1	cno	Variable Interest Entity Fixed Maturity Securities Fair Value VariableInterestEntityFixedMaturitySecuritiesFairValue	1017900000	usd
CY2023Q1	cno	Fair Value Fixed Maturity Securities Valued Using Broker Quotes Percentage FairValueFixedMaturitySecuritiesValuedUsingBrokerQuotesPercentage	0.86
CY2023Q1	cno	Variable Interest Entities Net Realized Gain Loss On Investments VariableInterestEntitiesNetRealizedGainLossOnInvestments	600000	usd
CY2023Q1	cno	Variable Interest Entities Net Gain Loss From Sale Of Fixed Maturity Investments VariableInterestEntitiesNetGainLossFromSaleOfFixedMaturityInvestments	2600000	usd
CY2023Q1	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	-2000000	usd
CY2023Q1	cno	Variable Interest Entity Investments Gross Investment Losses From Sale Before Tax VariableInterestEntityInvestmentsGrossInvestmentLossesFromSaleBeforeTax	2600000	usd
CY2023Q1	cno	Variable Interest Entities Investments Sold VariableInterestEntitiesInvestmentsSold	5600000	usd
CY2022Q1	cno	Variable Interest Entities Net Realized Gain Loss On Investments VariableInterestEntitiesNetRealizedGainLossOnInvestments	3200000	usd
CY2022Q1	cno	Variable Interest Entities Net Gain Loss From Sale Of Fixed Maturity Investments VariableInterestEntitiesNetGainLossFromSaleOfFixedMaturityInvestments	800000	usd
CY2022Q1	cno	Variable Interest Entities Change In Market Value Of Other Investments VariableInterestEntitiesChangeInMarketValueOfOtherInvestments	-200000	usd
CY2022Q1	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	2200000	usd
CY2022Q1	cno	Variable Interest Entity Investments Gross Investment Losses From Sale Before Tax VariableInterestEntityInvestmentsGrossInvestmentLossesFromSaleBeforeTax	800000	usd
CY2022Q1	cno	Variable Interest Entities Investments Sold VariableInterestEntitiesInvestmentsSold	11700000	usd
CY2023Q1	cno	Number Of Investments Held By Variable Interest Entities In Default NumberOfInvestmentsHeldByVariableInterestEntitiesInDefault	0	investment
CY2023Q1	cno	Investments Held In Limited Partnerships InvestmentsHeldInLimitedPartnerships	578500000	usd
CY2023Q1	cno	Unfunded Commitmentsto Limited Partnerships UnfundedCommitmentstoLimitedPartnerships	431000000	usd
CY2023Q1	cno	Available For Sale Fixed Maturities With Significant Unobservable Inputs Investment Grade Percent AvailableForSaleFixedMaturitiesWithSignificantUnobservableInputsInvestmentGradePercent	0.87
CY2023Q1	cno	Available For Sale Maturities With Significant Unobservable Inputs Corporate Securities Percent AvailableForSaleMaturitiesWithSignificantUnobservableInputsCorporateSecuritiesPercent	0.59

Files In Submission

Name	View Source	Status
0001224608-23-000026-index-headers.html	Edgar Link	pending
0001224608-23-000026-index.html	Edgar Link	pending
0001224608-23-000026.txt	Edgar Link	pending
0001224608-23-000026-xbrl.zip	Edgar Link	pending
cno-20230331.htm	Edgar Link	pending
cno-20230331.xsd	Edgar Link	pending
cno03312023ex311.htm	Edgar Link	pending
cno03312023ex312.htm	Edgar Link	pending
cno03312023ex321.htm	Edgar Link	pending
cno03312023ex322.htm	Edgar Link	pending
exhibit101-052023elgrestri.htm	Edgar Link	pending
exhibit102-052023elgpxshare.htm	Edgar Link	pending
exhibit103-052023restricted.htm	Edgar Link	pending
exhibit104-052023pxshare.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
cno-20230331_cal.xml	Edgar Link	unprocessable
cno-20230331_def.xml	Edgar Link	unprocessable
cno-20230331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cno-20230331_pre.xml	Edgar Link	unprocessable
cno-20230331_htm.xml	Edgar Link	completed
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CNO
CNO Financial Group, Inc. Stock $cno

2023 Q2 Form 10-Q Financial Statement

#000122460823000026 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNO CNO Financial Group, Inc. Stock $cno

2023 Q2 Form 10-Q Financial Statement

#000122460823000026 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNO
CNO Financial Group, Inc. Stock $cno